STOCK TITAN

Silence Therapeutics Plc American Depository Share - SLN STOCK NEWS

Welcome to our dedicated page for Silence Therapeutics Plc American Depository Share news (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics Plc American Depository Share stock.

Silence Therapeutics Plc (symbol: SLN) is a pioneering biotechnology company dedicated to developing innovative therapies by leveraging the body's natural RNA interference (RNAi) mechanism. This cutting-edge technology allows the selective inhibition of any gene in the genome, effectively silencing the production of disease-causing proteins.

Silence Therapeutics utilizes proprietary delivery systems to target therapeutic RNA molecules directly to specific cells, enhancing the specificity and efficacy of the treatment. The company's proprietary RNA chemistries and delivery systems are designed to improve the stability of these molecules and ensure efficient delivery, making their technology well-suited for treating life-threatening diseases.

The company's product pipeline includes two promising therapies:

  • SLN360: This therapy is designed to temporarily block the message of a specific gene associated with increased cardiovascular risk. By silencing the LPA gene, SLN360 lowers the levels of lipoprotein(a) [Lp(a)], potentially reducing the risk of heart diseases, heart attacks, and strokes.
  • SLN124: Aimed at addressing anemia, SLN124 targets the TMPRSS6 gene to prevent the liver from producing a hormone that controls iron levels in the body, hepcidin. By increasing hepcidin levels, SLN124 reduces iron levels in the blood, thereby promoting the production of healthy red blood cells.

Silence Therapeutics is at the forefront of RNAi-based therapies, with ongoing projects and collaborations to advance their groundbreaking treatments. For the latest updates on the company's achievements and developments, visit www.silence-therapeutics.com.

Rhea-AI Summary

Silence Therapeutics (Nasdaq: SLN) announced its participation in the Jefferies Global Healthcare Conference on June 6th at 2:30 p.m. ET. The company, known for its innovative biotechnology solutions aimed at silencing diseases through precision-engineered medicines, will provide a presentation accessible via live webcast on the company's investor section. An archived replay will also be available after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
conferences
-
Rhea-AI Summary

Silence Therapeutics (NASDAQ: SLN) disclosed its Q1 2024 financials and recent advancements. The firm reported a cash position of £152.8 million ($192.8 million), up from £62.9 million ($77.8 million) a year prior. Collaboration revenue rose by £1.0 million to £12.4 million, largely due to a £9.2 million milestone payment from AstraZeneca. R&D expenses decreased by £3.4 million to £9.2 million, and G&A expenses dropped by £1.3 million to £5.2 million. This resulted in a net loss of £1.9 million, a significant improvement from the £10.2 million loss last year.

Key pipeline updates included positive 36-week data from the phase 2 ALPACAR-360 study of zerlasiran for cardiovascular disease, with primary endpoints met and no new safety concerns. Additionally, promising phase 1 data for divesiran in polycythemia vera (PV) patients were reported. Collaboratively, Silence achieved a $10 million milestone from AstraZeneca after initiating a phase 1 trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
-
Rhea-AI Summary

Silence Therapeutics plc, Nasdaq: SLN, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The Company focuses on precision engineered medicines to silence diseases, aiming to transform people's lives. The event will take place on May 20th, 2:30 p.m. ET, with a live webcast accessible on the Silence website and an archived replay available post-conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
conferences
Rhea-AI Summary

Silence Therapeutics plc announced the retirement of Alistair Gray, an independent member of the Board of Directors since 2015, effective May 1, 2024. Alistair Gray made significant contributions during his tenure, marking a period of growth and transformation for the company under the leadership of Iain Ross and Craig Tooman. The Company transitioned into a global player focusing on RNA interference, developed a pipeline of innovative product candidates, and secured big pharma partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
management
-
Rhea-AI Summary
Silence Therapeutics plc, Nasdaq: SLN, announced positive results from the APOLLO phase 1 study of zerlasiran in reducing Lp(a) levels, a genetic risk factor for cardiovascular disease. The findings, published in JAMA, show sustained reductions in Lp(a) concentrations with well-tolerated profiles, promising advancements in addressing cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
-
Rhea-AI Summary
Silence Therapeutics plc, Nasdaq: SLN, reported positive topline 36-week data from an ongoing phase 2 study of zerlasiran in patients with high lipoprotein(a). The company also disclosed its financial results for the full year ended December 31, 2023, and highlighted recent business achievements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
Rhea-AI Summary
Silence Therapeutics plc (SLN) announced positive topline 36-week data from the ALPACAR-360 phase 2 study of zerlasiran for reducing Lp(a) levels in high-risk ASCVD patients. Zerlasiran demonstrated a highly significant reduction in Lp(a) levels, with a median percentage reduction of 90% or greater at week 36. Topline 48-week data is expected in 2Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
-
Rhea-AI Summary
Silence Therapeutics plc, Nasdaq: SLN, will release its financial and business results for Q4 and full year 2023 on March 13, 2024. The company will host a conference call to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences earnings
-
Rhea-AI Summary
Silence Therapeutics (SLN) announces a $10 million milestone payment from AstraZeneca for the initiation of a phase 1 clinical trial under their siRNA collaboration. This marks the first clinical milestone under their partnership and the third program to enter the clinic from their mRNAi GOLD™ platform. The collaboration aims to develop innovative therapies for cardiovascular, renal, metabolic, and respiratory diseases, with potential milestone payments of up to $140 million in development and $250 million in commercialization, along with tiered royalties on net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
Rhea-AI Summary
Silence Therapeutics plc (SLN) announced an oversubscribed private placement of 5,714,286 of the Company’s American Depositary Shares at a purchase price of US $21.00 per ADS, representing a premium of approximately 11% to Silence’s 30-day volume-weighted average price. The aggregate gross proceeds of the Private Placement are expected to be approximately US $120.0 million before deducting placement agent fees and other offering expenses. Investors in the Private Placement include 5AM Ventures, Frazier Life Sciences, Logos Capital, Nextech Invest Ltd, Redmile Group, TCGX, and Vivo Capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
none

FAQ

What is the current stock price of Silence Therapeutics Plc American Depository Share (SLN)?

The current stock price of Silence Therapeutics Plc American Depository Share (SLN) is $6.88 as of December 20, 2024.

What is the market cap of Silence Therapeutics Plc American Depository Share (SLN)?

The market cap of Silence Therapeutics Plc American Depository Share (SLN) is approximately 308.3M.

What is Silence Therapeutics Plc?

Silence Therapeutics Plc is a biotechnology company focused on developing medicines using RNA interference technology to silence disease-causing genes.

What is RNA interference (RNAi)?

RNA interference (RNAi) is a natural biological process where RNA molecules inhibit gene expression, effectively silencing specific genes.

What is SLN360 therapy?

SLN360 is a therapy designed to lower the levels of lipoprotein(a) [Lp(a)] by silencing the LPA gene, potentially reducing cardiovascular risks.

What is SLN124 therapy?

SLN124 aims to reduce anemia by silencing the TMPRSS6 gene, increasing hepcidin levels to lower blood iron and promote healthy red blood cell production.

How does Silence Therapeutics target specific cells?

The company uses proprietary delivery systems to direct therapeutic RNA molecules specifically to target cells, enhancing treatment specificity and efficacy.

What diseases are Silence Therapeutics' therapies targeting?

Silence Therapeutics' therapies target cardiovascular diseases, anemia, and potentially other life-threatening conditions through gene silencing.

How does SLN360 reduce cardiovascular risks?

SLN360 silences the LPA gene, lowering levels of Lp(a), which is associated with reduced risks of heart diseases, heart attacks, and strokes.

What is the role of hepcidin in SLN124 therapy?

Hepcidin is a hormone that controls iron levels in the body. SLN124 increases hepcidin levels to reduce blood iron and promote red blood cell production.

Where can I find more information about Silence Therapeutics' projects?

For more details on the company's projects and developments, visit their official website at www.silence-therapeutics.com.

What makes Silence Therapeutics unique?

Silence Therapeutics stands out for its proprietary RNAi technology and delivery systems, allowing precise and effective gene silencing to treat serious diseases.

Silence Therapeutics Plc American Depository Share

Nasdaq:SLN

SLN Rankings

SLN Stock Data

308.31M
38.16M
16.94%
62.77%
0.76%
Biotechnology
Healthcare
Link
United States of America
London